- Home
- PKBK vs NGNE Comparison
PKBK vs NGNE Comparison
Compare PKBK & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- NGNE
- Stock Information
- Founded
- PKBK 1999
- NGNE 2003
- Country
- PKBK United States
- NGNE United States
- Employees
- PKBK 108
- NGNE N/A
- Industry
- PKBK Major Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- NGNE Health Care
- Exchange
- PKBK Nasdaq
- NGNE Nasdaq
- Market Cap
- PKBK 241.2M
- NGNE 251.9M
- IPO Year
- PKBK N/A
- NGNE N/A
- Fundamental
- Price
- PKBK $21.48
- NGNE $20.09
- Analyst Decision
- PKBK
- NGNE Strong Buy
- Analyst Count
- PKBK 0
- NGNE 7
- Target Price
- PKBK N/A
- NGNE $41.86
- AVG Volume (30 Days)
- PKBK 25.1K
- NGNE 240.1K
- Earning Date
- PKBK 07-18-2025
- NGNE 08-08-2025
- Dividend Yield
- PKBK 3.35%
- NGNE N/A
- EPS Growth
- PKBK 24.08
- NGNE N/A
- EPS
- PKBK 2.41
- NGNE N/A
- Revenue
- PKBK $64,206,999.00
- NGNE $925,000.00
- Revenue This Year
- PKBK N/A
- NGNE N/A
- Revenue Next Year
- PKBK N/A
- NGNE N/A
- P/E Ratio
- PKBK $8.93
- NGNE N/A
- Revenue Growth
- PKBK N/A
- NGNE N/A
- 52 Week Low
- PKBK $15.44
- NGNE $6.88
- 52 Week High
- PKBK $24.29
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PKBK 71.48
- NGNE 57.57
- Support Level
- PKBK $20.37
- NGNE $14.65
- Resistance Level
- PKBK $20.92
- NGNE $18.21
- Average True Range (ATR)
- PKBK 0.49
- NGNE 1.84
- MACD
- PKBK 0.20
- NGNE 0.03
- Stochastic Oscillator
- PKBK 96.09
- NGNE 80.24
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.